These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32448109)

  • 1. Overview of Therapeutic Drugs and Methods for the Treatment of Parkinson's Disease.
    Schneider A; Sari AT; Alhaddad H; Sari Y
    CNS Neurol Disord Drug Targets; 2020; 19(3):195-206. PubMed ID: 32448109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease.
    Petzer JP; Castagnoli N; Schwarzschild MA; Chen JF; Van der Schyf CJ
    Neurotherapeutics; 2009 Jan; 6(1):141-51. PubMed ID: 19110205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-dopaminergic treatments for motor control in Parkinson's disease.
    Fox SH
    Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
    Oertel W; Schulz JB
    J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
    Gray R; Patel S; Ives N; Rick C; Woolley R; Muzerengi S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE;
    JAMA Neurol; 2022 Feb; 79(2):131-140. PubMed ID: 34962574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternatives to levodopa in the initial treatment of early Parkinson's disease.
    Lees A
    Drugs Aging; 2005; 22(9):731-40. PubMed ID: 16156677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.
    ; Gray R; Ives N; Rick C; Patel S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE
    Lancet; 2014 Sep; 384(9949):1196-205. PubMed ID: 24928805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside.
    Alborghetti M; Nicoletti F
    Curr Neuropharmacol; 2019; 17(9):861-873. PubMed ID: 30160213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Strategies in Early Parkinson's Disease.
    Marsili L; Marconi R; Colosimo C
    Int Rev Neurobiol; 2017; 132():345-360. PubMed ID: 28554414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of oral adenosine A(2A) antagonist istradefylline for the treatment of moderate to severe Parkinson's disease.
    Vorovenci RJ; Antonini A
    Expert Rev Neurother; 2015; 15(12):1383-90. PubMed ID: 26630457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.
    Caslake R; Macleod A; Ives N; Stowe R; Counsell C
    Cochrane Database Syst Rev; 2009 Oct; (4):CD006661. PubMed ID: 19821381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent developments in the pharmacological treatment of Parkinson's disease.
    Tuite P; Riss J
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1335-52. PubMed ID: 12882620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs used to treat Parkinson's disease, present status and future directions.
    Abdel-Salam OM
    CNS Neurol Disord Drug Targets; 2008 Oct; 7(4):321-42. PubMed ID: 18991661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoamine Oxidase B Inhibitors in Parkinson's Disease.
    Dezsi L; Vecsei L
    CNS Neurol Disord Drug Targets; 2017; 16(4):425-439. PubMed ID: 28124620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor.
    Malmlöf T; Feltmann K; Konradsson-Geuken Å; Schneider F; Alken RG; Svensson TH; Schilström B
    J Neural Transm (Vienna); 2015 Feb; 122(2):259-72. PubMed ID: 24906468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
    Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A
    Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled trials.
    Yan R; Cai H; Cui Y; Su D; Cai G; Lin F; Feng T
    Eur J Neurol; 2023 Apr; 30(4):1118-1134. PubMed ID: 36437702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.
    Löhle M; Reichmann H
    BMC Neurol; 2011 Sep; 11():112. PubMed ID: 21939547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's Disease.
    McIntosh E; Kent S; Gray A; Clarke CE; Williams A; Jenkinson C; Ives N; Patel S; Rick C; Wheatley K; Gray R;
    Mov Disord; 2021 Sep; 36(9):2136-2143. PubMed ID: 33960511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An MCASE approach to the search of a cure for Parkinson's Disease.
    Klopman G; Sedykh A
    BMC Pharmacol; 2002 Apr; 2():8. PubMed ID: 11926966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.